secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001171843-22-003216
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M
--------------------------------------------------------------------------------

- Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.
- Cash, equivalents and marketable securities $183.2M at March 31, 2022; runway into first half 2024.
- Terminated STOPS and ASO HBV programs in Q1 due to insufficient antiviral activity and poor tolerability.
- ALG-000184 (HBV CAM) 28-day top-line data expected Q2 2022; 12-week cohort initiating Q3.
- COVID PI candidate ALG-097558 7-20x more potent than nirmatrelvir vs variants; Phase 1 CTA planned H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/0001171843-22-003216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/f8k_050422.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer